Current Clinical Trials
BAMF Health is currently conducting the following advanced clinical trials for prostate cancer
ECLIPSE Trial A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Protocol Title: A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Short Name: ECLIPSE Trial
Description: This is a prospective, open-label, multi-center, randomized, Phase 3 study evaluating Lutetium 177Lu-PSMA-I&T as treatment compared to standard of care hormone therapy in men with metastatic Castration-Resistant Prostate Cancer.
The study will include a total of 400 patients with metastatic prostate cancer and documented positive PSMA PET imaging. Patients will be randomized at a ratio of 2:1 to receive either 177Lu-PSMA-I&T or hormone therapy (abiraterone or enzalutamide) respectively. Patients randomized to the investigational product will receive up to 4 treatments every 6 weeks at a dose of 200 mCi (7.4 GBq). All patients will be followed for adverse events and safety labs throughout the course of the study. Progression of disease will be assessed radiographically using Prostate Working Group Criteria 3 (PWGC3) and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of conventional imaging as well as PSA levels and symptom recording throughout the course of treatment.
Patient Enrollment at BAMF: September 12, 2022
Number of patients to be enrolled (study wide): 400
Number of clinical sites in the US: 25 at present
Patient Eligibility Criteria: please see the complete list at:
In short, men 18 or older with metastatic castration resistant prostate adenocarcinoma without predominant small cell component who have previously been treated with a next-generation androgen receptor-directed therapy and have had progression, but have not had chemotherapy (docetaxel or cabazitaxel).
To get more information or be connected to discuss this clinical trial with someone at BAMF Health, please complete this form
SABRE Trial The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with PSMA-negative biochemical recurrence of prostate cancer following definitive therapy.
More information coming soon
Future Clinical Trials
BAMF Health will soon begin to host clinical trials for many forms of cancer and disease states. To participate in the BAMF Health Clinical Trial Platform, your physician must refer you to our team.
Please fill out this form so that our team may alert you when a trial opens for your type of cancer or disease